Spots Global Cancer Trial Database for A Study of Genetic Based Chemotherapy Dosing for Breast Cancer Patients
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of Genetic Based Chemotherapy Dosing for Breast Cancer Patients
Official Title: Pharmacogenetic Dosing of Epirubicin in FEC Chemotherapy
Study ID: NCT01740271
Conditions
Interventions
Study Description
Brief Summary: Epirubicin is a common chemotherapy medication used in the treatment of breast cancer. However, chemotherapy dosing is calculated based on people's height and weight, which may not be the most accurate way. The purpose of this study is to see if epirubicin dosing based on people's genetic profiles is better than the usual methods.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Cross Cancer Institute, Edmonton, Alberta, Canada
Contact Details
Name: Michael B Sawyer, MD FRCPC BScPharm
Affiliation: Alberta Health services
Role: PRINCIPAL_INVESTIGATOR
Name: John R Mackey, MD FRCPC
Affiliation: Alberta Health services
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
